2016 American Transplant Congress
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the SIMCER Study.
Introduction: Long-term post-liver transplant (LTx) complications, particularly impaired renal function (RF) and its consequences, remain a concern. Presented here are the results of the SIMCER…2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
1Univ of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…2015 American Transplant Congress
Remote Ischemic Preconditioning Increases Transplantation of Abdominal Organs in Standard Criteria Neurological Death Donors
Background: Remote ischemic preconditioning (RIPC) induces innate protective mechanisms in remote organs. We hypothesized RIPC soon after neurological death (ND) would improve donor organ function…2015 American Transplant Congress
Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study
Surgery, Hopkins, Baltimore, MD.
A single center study has demonstrated a two-fold survival benefit of incompatible live donor kidney transplant (ILDKT) compared to remaining on dialysis. We sought to…2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…2015 American Transplant Congress
Multicenter Study to Develop a Novel Prediction Index for Hepatocellular Carcinoma (HCC) Recurrence After Liver Transplant (LT)
1UCSF, San Francisco, CA; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Jacksonville, FL.
Several factors have been associated with a high risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), but no reliable risk score has…2015 American Transplant Congress
Explorative Analysis of ZEUS After 5 Years: Histological Assessment from Biopsy Analyses
1ZEUS Study Group, Germany; 2Novartis, Pharma, Germany; 3ZEUS Study Group, Switzerland.
Background: Analysis of pathologists' assessments and histological data allow for deeper insight on patient outcome together with investigator's final clinical diagnoses. Here we present 5…2015 American Transplant Congress
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 48
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To follow up on renal function (GFR) at month (Mo) 48 after kidney transplantation (Tx) in patients (pts) on immunosuppressive regimen with different calcineurin…2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
1ZEUS Study Group, Germany; 2ZEUS Study Group, Switzerland; 3Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…
- « Previous Page
- 1
- …
- 11
- 12
- 13